Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2011 Sep 1.
Published in final edited form as: Hypertension. 2010 Aug 2;56(3):331–334. doi: 10.1161/HYPERTENSIONAHA.110.156810

Breathing life into the lifecourse approach: Pregnancy history and cardiovascular disease in women

Janet W Rich-Edwards 1,2, Thomas F McElrath 3, Ananth Karumanchi 4, Ellen W Seely 5
PMCID: PMC2948753  NIHMSID: NIHMS229333  PMID: 20679178

The lifecourse approach to epidemiology has broadened our understanding of chronic disease as a developmental process that evolves over the entire lifespan. Subclinical syndromes at an early phase in life may offer insights into later health that are not presently recognized. For example, a woman’s reproductive history is an often overlooked predictor of later chronic disease.1 Increasing evidence suggests that pregnancy complications unmask predisposition to cardiovascular disease, and may serve as cardiovascular risk markers particular to women.2 As cardiovascular disease is the leading cause of death among women, an understanding of the ways in which pregnancy complications presage risk – or possibly alter risk - can further the understanding of cardiovascular disease mechanisms.

In 2002, Sattar and Greer suggested that pregnancy constitutes a physiologic “stress test” that reveals latent chronic disease3 (Figure 1A). They highlighted the implications for future maternal cardiovascular risk of four common pregnancy complications: gestational diabetes, hypertensive disorders, low birthweight delivery (<2500g), and preterm delivery (<37 weeks). For brevity, we refer here to this group of syndromes as “complicated pregnancies,” recognizing that less prevalent pregnancy complications may also predict cardiovascular risk. As a group, these complicated pregnancies are characterized by inflammation, vasculopathy, altered angiogenesis, thrombosis and insulin resistance – pathophysiologic processes common to coronary heart disease and stroke. Our intent is to update the growing literature, outline research needs, and question whether it is time to incorporate pregnancy history into cardiovascular risk assessment.

Figure 1.

Figure 1

Pregnancy is a “stress test” that can reveal subclinical trajectories and identify new opportunities for chronic disease prevention (adapted with permission from Sattar N and Greer I, BMJ 2002;325:157–160).

1A. Women at high risk of future cardiovascular disease are identifiable during pregnancy, at which point subclinical vascular risk may become clinically evident

1B. The risk revealed by pregnancy can be used to target high-risk women for screening and early intervention by lifestyle modification and treatment, altering their chronic disease trajectories as they enter middle age

Gestational diabetes (GDM) affects as many as 5% of pregnancies. Since the 1980s, it has been clear that GDM has major implications for the mother beyond pregnancy: roughly half of women with prior GDM will develop type 2 diabetes (T2DM) within 10 years.4 The Fifth International Workshop-Conference on Gestational Diabetes and the American Diabetes Association recommended enhanced glucose testing schedules for women with a GDM history.45 Despite these recommendations, rates of T2DM screening remain low in women with a history of GDM.6 A GDM diagnosis may also provide a window of opportunity for diabetes prevention,7 as risk for T2DM may be lowered with a lifestyle modification8 or medication.9 Such preventive interventions may also avert cardiovascular disease, as suggested by a finding of 70% higher risk of cardiovascular disease among women with a GDM history.10 The increased risk is attributable largely to T2DM,10 but may also stem from abnormal vascular function among women with GDM who have not developed T2DM.11

Preeclampsia is a hypertensive disorder of pregnancy that affects roughly 5% of pregnancies.12 Former preeclamptics have roughly four-fold higher incidence of hypertension and twice the risks of heart disease, stroke, and venous thromboembolism.13 Recurrent preeclampsia has been associated with end stage renal disease and hypothyroidism.1415 Preeclampsia has been associated with insulin resistance, endothelial dysfunction and anti-angiogenic factors in maternal circulation;16 these and other cardiovascular risk factors may predate preeclamptic pregnancies17 and simply persist postpartum. On the other hand, preeclampsia itself may be a risk factor for future cardiovascular disease, through persistent subclinical systemic vascular damage or endothelial dysfunction occurring in women who were healthy prior to the onset of preeclampsia – however, definitive evidence for this hypothesis is lacking.

Preterm delivery (<37 weeks’ gestation) accounts for over 12% of deliveries in the United States and 5–9% of deliveries elsewhere in the developed world. Mothers who have delivered preterm infants have at least double the risk of cardiovascular disease.1821 The strength and nature of the association of preterm delivery with future cardiovascular risk likely depends on whether the preterm birth was medically indicated or spontaneous, as well as any precipitating complications. The main indications for medically indicated preterm births are preeclampsia and fetal growth restriction. It is not clear how much of the association of preterm delivery with cardiovascular risk is driven by preeclampsia as the indication for early delivery. The combination of preterm delivery and preeclampsia is particularly predictive of future risk of cardiovascular disease, with 7-fold higher risks for women with preterm preeclamptic pregnancies compared with normotensive term deliveries.18

Spontaneous preterm birth has a clinical profile reminiscent of cardiovascular risk. Women with a history of spontaneous preterm delivery have higher inflammatory levels, larger waist circumference, and dyslipidemia years after delivery.22 The extent to which spontaneous preterm birth predicts cardiovascular events is presently unknown, but is suggested by the three-fold increased risk of cardiovascular mortality observed among women with a history of non-preeclamptic preterm deliveries, a high proportion of which are likely spontaneous.18

Neonatal birthweight predicts maternal lifespan.2327 Maternal cardiovascular mortality drops by 25% per standard deviation higher birthweight.25 Low birthweight (<2500g) infants comprise about 8% of births; their mothers have double the risk of cardiovascular mortality of mothers of normal birthweight infants (3500g).2326 Low neonatal birth weight usually results from intrauterine growth restriction or from preterm birth resulting in a neonate appropriate for gestational age but smaller than term. As these reasons for low birthweight differ in their pathogenesis, their links to cardiovascular risk prediction may differ as well.

By the age of menopause, we estimate that at least 20% of all women will have had a pregnancy complicated by diabetes, preeclampsia, a low birthweight infant, or preterm delivery. This figure is undoubtedly higher for African American women, who are 50% to 100% more likely than white mothers to have poor pregnancy outcomes28 and 30% more likely to die from cardiovascular disease than white women.29

A full understanding of the utility of pregnancy history for cardiovascular disease prevention requires multidisciplinary efforts from epidemiologists, basic researchers and patient oriented researchers. Clinically, we need to integrate the pregnancy care delivered by obstetricians and nurse midwives with primary care performed by internists. Although electronic medical records should aid in this integration, alterations in beliefs regarding the utility of reproductive events in predicting cardiovascular disease may require changes in provider training.

Several steps are prompted by the emerging data linking complicated pregnancies with cardiovascular risk. To maximize the utility of the pregnancy history, we need to:

  1. Fully characterize the trajectories that lead from complicated pregnancies to cardiovascular events for different populations of women. It will be important to determine the extent to which these overlapping pregnancy complications predict cardiovascular risk independent of each other. For example, to what extent is does a history of preterm birth predict future CVD risk after accounting for preeclampsia? We also need to identify the particular definitions and combinations of pregnancy complications that are the most sensitive and specific for predicting cardiovascular disease in maturity. For example, is cardiovascular risk best – and most simply -predicted by the history of any of these four complications, or is it more effective to capture the joint occurrence of particular complications, such as preterm preeclampsia? The answers to these questions require large longitudinal datasets that include data on pregnancy complications, cardiovascular risk factors, lifestyle risk factors, and cardiovascular events.

  2. Determine the time course from complicated pregnancies to the first emergence of cardiovascular risk factors to develop screening schedules for women with and without particular pregnancy complications. We already have screening recommendations for women with a history of gestational diabetes; should we develop similar guidelines for lipid screening for women who have delivered preterm? Directed research to determine the predictive value of pregnancy complications will enable the development of such recommendations.

  3. Determine the independent contribution of complicated pregnancies to CVD risk, above and beyond the suite of cardiovascular risk factors that are screened as routine preventive care. Would pregnancy history add to the prognostic value of cardiovascular risk scoring systems such as the Framingham or Reynolds scores?

  4. Develop partnerships between researchers, clinicians, and information systems managers to link prenatal to primary care records, so that women’s primary care providers are alerted to the pregnancy history of their parous patients.

  5. Promote truly translational research to establish experimental animal models to determine whether pregnancy complications may exacerbate underlying endothelial dysfunction leading to novel organ damage in the mother, increasing her risk of future disease, or whether complications are simply markers of latent disease risk.

  6. Foster obstetric and internal medicine cross-training: Include obstetrical rotations or electives in internal medicine residencies and continue to require internal medicine rotations in obstetrical training

The stress test of pregnancy provides glimpses into the otherwise silent early adult years in which chronic disease trajectories are set – yielding important prognostic data at an early life phase when targeted prevention is more timely and effective. Researchers need to elucidate the specific pathways through which complicated pregnancies predict and/or cause cardiovascular disease, and to explore the utility of detailed pregnancy history as an essential part of women’s clinical history. We have the opportunity to change disease trajectories before they emerge as chronic disease at menopause (Figure 1B). It is time to breathe life into the lifecourse approach by applying our growing knowledge of the importance of pregnancy history to prevent and better treat cardiovascular disease in women.

Acknowledgments

We are thankful to Dr. Susan Mason and Ms. Eileen Hibert for assistance in estimating the lifetime prevalence of complicated pregnancies and to Mr. Michael Cichanowski for preparing the figure.

This research was conducted with the support of a pilot grant from Harvard Catalyst | The Harvard Clinical and Translational Science Center (NIH Grant #1 UL1 RR 025758-02 and financial contributions from participating institutions). The funding body had no input or influence on the contents of this paper.

Footnotes

Dr. Rich-Edwards drafted the manuscript, and Drs. Seely, McElrath and Karumanchi provided important content and editorial revisions.

The authors have no conflicts of interest to report.

References

  • 1.Rich-Edwards JW. Reproductive health as a sentinel of chronic disease in women. Women's Health. 2009;5:101–105. doi: 10.2217/17455057.5.2.101. [DOI] [PubMed] [Google Scholar]
  • 2.Dzau VJ. Markers of malign across the cardiovascular continuum: interpretation and application. Circulation. 2004;109:IV1–IV2. doi: 10.1161/01.CIR.0000133445.78855.aa. [DOI] [PubMed] [Google Scholar]
  • 3.Sattar N, Greer IA. Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening? British Medical Journal. 2002;325:157–160. doi: 10.1136/bmj.325.7356.157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Metzger BE, Buchanan TA, Coustan DR, De Leiva A, Dunger DB, Hadden DR, Hod M, Kitzmiller JL, Kjos SL, Oats JN, Pettitt DJ, Sacks DA, Zoupas C. Summary and recommendations of the Fifth International Workshop Conference on Gestational Diabetes Mellitus. Diabetes Care. 2007;30:s251–s260. doi: 10.2337/dc07-s225. [DOI] [PubMed] [Google Scholar]
  • 5.American Diabetes Association. Standards of medical care in diabetes—2008. Diabetes Care. 2008;31:S1254. doi: 10.2337/dc08-S012. [DOI] [PubMed] [Google Scholar]
  • 6.Kim C, Tabaei BP, Burke R, McEwen LN, Lash RW, Johnson SL, Schwartz KL, Bernstein SJ, Herman WH. Missed opportunities for type 2 diabetes mellitus screening among women with a history of gestational diabetes mellitus. American Journal of Public Health. 2006;96:1–6. doi: 10.2105/AJPH.2005.065722. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Bentley-Lewis R, Levkoff S, Stuebe A, Seely EW. Gestational diabetes mellitus: postpartum opportunities for the diagnosis and prevention of type 2 diabetes mellitus. Nature Clinical Practice Endocrinology & Metabolism. 2008;4:552–558. doi: 10.1038/ncpendmet0965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine. 2002;346:393–403. doi: 10.1056/NEJMoa012512. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP. Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes. 2002;51:2796–2803. doi: 10.2337/diabetes.51.9.2796. [DOI] [PubMed] [Google Scholar]
  • 10.Shah BR, Retnakaran R, Booth GL. Increased risk of cardiovascular disease in young women following gestational diabetes mellitus. Diabetes Care. 2008;31:1668–1669. doi: 10.2337/dc08-0706. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Heitritter SM, Solomon CG, Mitchell GF, Skali-Ounis N, Seely EW. Subclinical inflammation and vascular dysfunction in women with previous gestational diabetes mellitus. Journal of Clinical Endocrinology and Metabolism. 2005;90:3983–3988. doi: 10.1210/jc.2004-2494. [DOI] [PubMed] [Google Scholar]
  • 12.Thadhani R, Solomon CG. Preeclampsia-a glimpse into the future? New England Journal of Medicine. 2008;359:858–860. doi: 10.1056/NEJMe0804637. [DOI] [PubMed] [Google Scholar]
  • 13.Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. British Medical Journal. 2007;335:974. doi: 10.1136/bmj.39335.385301.BE. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Vikse BE, Irgens LM, Leivestad T, Skjaerven R, Iversn BM. Preeclampsia and the risk of end-stage renal disease. New England Journal of Medicine. 2008;395:800–809. doi: 10.1056/NEJMoa0706790. [DOI] [PubMed] [Google Scholar]
  • 15.Levine RJ, Vatten LJ, Horowitz GL, Qian C, Romundstad PR, Yu KF, Hollenberg AN, Hellevik AI, Asvold BO, Karumanchi SA. Preeclampsia, soluble fms-like tyrosine kinase 1, and the risk of reduced thyroid function. British Medical Journal. 2009;339:b4336. doi: 10.1136/bmj.b4336. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Thadhani R, Ecker JL, Mutter WP, Wolf M, Smirnakis KV, Sukhatme VP, Levine RJ, Karumanchi SA. Insulin resistance and alterations in angiogenesis: additive insults that may lead to preeclampsia. Hypertension. 2004;43:988–992. doi: 10.1161/01.HYP.0000124460.67539.1d. [DOI] [PubMed] [Google Scholar]
  • 17.Magnussen EB, Vatten LJ, Lund-Nilsen TI, Salvesen KA, Davey-Smith G, Romundstad PR. Prepregnancy cardiovascular risk factors as predictors of pre-eclampsia: population based cohort study. British Medical Journal. 2007;335:978–981. doi: 10.1136/bmj.39366.416817.BE. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. British Medical Journal. 2001;323:1213–1217. doi: 10.1136/bmj.323.7323.1213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Smith G, Whitley E, Gissler E, Hemminki E. Birth dimensions of offspring, premature birth, and the mortality of mothers. Lancet. 2000;336:2066–2067. doi: 10.1016/S0140-6736(00)03406-1. [DOI] [PubMed] [Google Scholar]
  • 20.Smith GD, Pell JP, Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129 290 births. Lancet. 2001;357:2002–2006. doi: 10.1016/S0140-6736(00)05112-6. [DOI] [PubMed] [Google Scholar]
  • 21.Smith GD, Sterne J, Tynelius P, Lawlor DA, Rasmussen F. Birth weight of offspring and subsequent cardiovascular mortality of the parents. Epidemiology. 2005;16:563–569. doi: 10.1097/01.ede.0000164790.96316.c0. [DOI] [PubMed] [Google Scholar]
  • 22.Catov JM, Bodnar LM, Ness RB, Barron SJ, Roberts JM. Inflammation and dyslipidemia related to risk of spontaneous preterm birth. American Journal of Epidemiology. 2007;166:1312–1319. doi: 10.1093/aje/kwm273. [DOI] [PubMed] [Google Scholar]
  • 23.Davey-Smith G, Harding S, Rosato M. Relation between infants' birth weight and mothers' mortality: prospective observational study. British Medical Journal. 2000;320:839–840. doi: 10.1136/bmj.320.7238.839. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Davey-Smith G, Hart C, Ferrell C, Upton M, Hole D, Hawthorne V, Watt G. Birth weight of offspring and mortality in the Renfrew and Paisley study: prospective observational study. British Medical Journal. 1997;315:1189–1193. doi: 10.1136/bmj.315.7117.1189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Davey-Smith G, Hypponen E, Power C, Lawlor DA. Offspring birth weight and parental mortality: prospective observational study and meta-analysis. American Journal of Epidemiology. 2007;166:160–169. doi: 10.1093/aje/kwm054. [DOI] [PubMed] [Google Scholar]
  • 26.Davey-Smith G, Whitley E, Gissler M, Hemminki E. Birth dimensions of offspring, premature birth, and the mortality of mothers. Lancet. 2000;356:2066–2067. doi: 10.1016/S0140-6736(00)03406-1. [DOI] [PubMed] [Google Scholar]
  • 27.Catov JM, Newman AB, Roberts JM, Kelsey SF, Sutton-Tyrrell K, Colbert L, Rubin SM, Satterfield S, Ness RB Health ABC Study. Preterm delivery and later maternal cardiovascular disease risk. Epidemiology. 2007;18:733–739. doi: 10.1097/EDE.0b013e3181567f96. [DOI] [PubMed] [Google Scholar]
  • 28.Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Menacker F, Kirmeyer S, Mathews TJ Vital Statistics Do. National vital statistics reports: births: final data for 2006. Centers for Disease Control and Prevention; 2009. [Google Scholar]
  • 29.Statistical Fact Sheet — Populations 2009 Update. [Accessed June 10, 2009];African Americans and Cardiovascular Diseases - Statistics. 2009 Available at: http://www.americanheart.org/downloadable/heart/1237138562702AFR_AM_NEW.pdf.

RESOURCES